pyrimidine has been researched along with Carcinoma, Non-Small Cell Lung in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, GD; Chen, IC; Chuang, YH; Del Caño-Ochoa, F; Ho, CC; Ko, CJ; Ku, CC; Lan, SW; Lee, CF; Lee, CT; Lee, DY; Lee, MS; Lin, HH; Lin, HY; Ramón-Maiques, S; Tu, HF | 1 |
| Agarwal, SM; Gupta, M; Pal, D; Saini, R | 1 |
| Bezwada, D; Byers, LA; Cai, L; Castrillon, DH; Chen, BPC; Choi, E; DeBerardinis, RJ; Faubert, B; Girard, L; Heymach, JV; Hu, Z; Huffman, KE; Kim, J; Lambrechts, D; Li, K; Lin, YF; Minna, JD; Ni, M; Peña, CG; Rodriguez-Canales, J; Unsal-Kacmaz, K; Vansteenkiste, J; Villalobos, P; Wauters, E; Wistuba, I; Xu, J | 1 |
| Choowongkomon, K; Gleeson, MP; Hannongbua, S; Suphakun, P; Toviwek, B | 1 |
| Baek, B; Hyun, SY; Kim, B; Kim, Y; Lee, HJ; Lee, HY; Lee, J; Min, HY; Pham, PC | 1 |
| Collins, C; D'Alessandro, A; Daniels, MW; Danis, E; DeGregori, J; Gao, D; Gehrke, S; Paola, JTD; Pham-Danis, C; Rozhok, AI | 1 |
| Cheng, P; Goggi, JL; Haslop, A; Jiang, L; Ramasamy, B; Robins, EG; Soh, V | 1 |
| Kim, D; Kwon, A; Lee, BY; Min, KH; Nguyen, HK; Song, J; Suh, W; Yoo, J | 1 |
| Broekhuizen, AJ; Giovannetti, E; Hubeek, I; Kaspers, GJ; Pastor-Anglada, M; Peters, GJ | 1 |
| Fandzloch, M; Popławska, B; Sitkowski, J; Łakomska, I | 1 |
1 review(s) available for pyrimidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Purines; Pyridones; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2017 |
9 other study(ies) available for pyrimidine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD.
Topics: Afatinib; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Deoxyribonucleases; Drug Therapy, Combination; Humans; Immunomodulating Agents; Lung Neoplasms; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Pyrimidines | 2021 |
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Topics: Ammonia; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Bicarbonates; Carbamoyl-Phosphate Synthase (Ammonia); Carbamyl Phosphate; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Proliferation; DNA; DNA Damage; DNA Replication; DNA-Directed DNA Polymerase; Female; Gene Silencing; Humans; Lung Neoplasms; Male; Metabolomics; Mice; Mitochondria; Nitrogen; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; S Phase; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.
Topics: A549 Cells; Amines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Lung Neoplasms; Pyrimidines; Solubility; Structure-Activity Relationship; Sulfonamides | 2017 |
Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imidazoles; Immunohistochemistry; MCF-7 Cells; Pyrazines; Pyrimidines; Receptor, IGF Type 1; Receptors, Somatomedin; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.
Topics: Carbamoyl-Phosphate Synthase (Ammonia); Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Respiration; ErbB Receptors; Glycolysis; HEK293 Cells; Humans; Lung Neoplasms; Metabolomics; Mitochondria; Mutation; Prognosis; Pyrimidines; Signal Transduction; Urea | 2019 |
Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Isotope Labeling; Lung Neoplasms; Male; Mice; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Tissue Distribution | 2019 |
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cattle; Cell Line, Tumor; Equilibrative Nucleoside Transporter 1; Gene Expression Regulation; Humans; Lung Neoplasms; Membrane Transport Proteins; Pyrimidines; RNA, Messenger; Substrate Specificity | 2008 |
Platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo [1,5-a]pyrimidines: spectroscopical characterization and cytotoxic activity in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Magnetic Resonance Spectroscopy; Organoplatinum Compounds; Pyrimidines; Triazoles | 2012 |